GRAY News and Press, Graybug Vision Inc. From 08/04/21

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chie...

Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...

Marcelo Ricardo Daros/iStock via Getty Images Adding more than a quarter of its value today so far, clinical-stage biopharmaceutical company Graybug Vision ([[GRAY]] +26.5%) is on course to record its biggest one-day gain since December. ~19.2M Graybug shares have changed hands today, indicat...

Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis ...

Gainers: Enochian Biosciences ENOB +127%, RAPT Therapeutics RAPT +101%, iTeos Therapeutics ITOS +37%, Novan NOVN +30%, Anavex Life Sciences AVXL +23%.Losers: Avenue Therapeutics ATXI -39%, Inhibikase Therapeutics (IKT) -21%, ...

Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...

Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...

Graybug Vision ([[GRAY]] -7.2%) has reported the results from full-data analysis of the Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD).Conducted across 33 sites in the U.S., the masked and controlled trial was designed to evalu...

Graybug Vision (GRAY): Q1 GAAP EPS of -$0.54 misses by $0.08.As of March 31, 2021, the company’s cash, cash equivalents, and short-term investments totaled $85.7 million, compared to $95.0 million as of December 31, 2020. The decrease was primarily due to the loss from operations of $1...

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate dev...